Recombinant interferon alpha and gamma in combination as treatment for XXXX .

@entity1 @entity137 @entity3692 @entity5 @entity1358
Fifty-three @entity1 with @entity1358 received treatment with combinations of recombinant alpha (rIFN-alpha-2a) and gamma ( @entity3692 ) interferons on three different treatment schedules. On treatment schedule A, 13 @entity1 received i.m. rIFN-alpha-2a and @entity3692 simultaneously at a 1:1 ratio by dose units (2 X 10(6) U/m2), equivalent to a 1:10 ratio by protein weight. Results included severe constitutional symptoms in 62% of the @entity1 and no partial remissions (PR) or complete remissions among 10 evaluable @entity1 . On treatment schedule B, 25 @entity1 received an i.m. injection of rIFN-alpha-2a and @entity3692 simultaneously at a 1:1 ratio by protein weight (2 X 10(6) U/m2 and 2 X 10(5) U/m2, respectively). This schedule was well tolerated, allowing a 25-50% increment in over 75% of the @entity1 . Four @entity1 (16%) achieved PR. On treatment schedule C, 15 @entity1 received alternating weekly therapy: first @entity3692 /m2 daily for 7 days) followed by rIFN-alpha-2a (10 X 10(6) U/m2 daily for 7 days). One of 13 evaluable @entity1 in treatment schedule C achieved an 80% @entity5 reduction and was rendered free of disease after the primary @entity5 was resected. @entity137 was similar in nature to that of rIFN-alpha-2a or @entity3692 separately. The @entity137 of treatment schedule A suggested additive toxic effects. No distinct synergistic antitumor effect was observed.
